Browse the evidence

Older ICU patients (>60 years) require higher protein intakes (approaching 2.0–2.5 g/kg/day) to achieve positive nitrogen balance and stimulate muscle protein synthesis, due to age-related anabolic resistance.

If you are over 60 and in the ICU, your body needs significantly more protein than the standard recommendation to stop muscle loss. Aim for 2.0 to 2.5 grams of protein per kilogram of your usual body weight daily, prioritizing high-quality proteins rich in leucine. This is safe unless you have severe kidney failure. Combine this nutrition with early physical therapy or movement to maximize muscle retention.

Adjunct treatment with once-weekly semaglutide (up to 1.0 mg) produces sustained, clinically significant weight loss (mean 14.7% total weight loss) in post-bariatric patients with weight regain or insufficient weight loss over 12 months, regardless of sex or initial surgery type.

If you have regained weight or lost insufficient weight after bariatric surgery, semaglutide (a GLP-1 medication) can help you lose more weight, even if you don't have diabetes. In this study, patients lost an average of 14.7% of their body weight over a year using a dose lower than the maximum approved for obesity. This offers a medical option when lifestyle changes alone are not enough, potentially avoiding the need for revision surgery.

In patients with Class 3 obesity and Type 2 Diabetes, switching to weight-neutral or weight-losing diabetes medications (SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors) during a multidisciplinary weight management program results in significantly greater weight loss compared to switching to weight-gaining medications (sulphonylureas, insulin).

If you have severe obesity (BMI 40+) and Type 2 Diabetes, ask your doctor about switching your diabetes medications to 'weight-neutral' or 'weight-losing' types (like SGLT-2 inhibitors or GLP-1 agonists) instead of older 'weight-gaining' ones (like insulin or sulphonylureas). In this program, patients who made this switch lost nearly 8% of their body weight in 6 months, compared to only 2.4% for those who switched to weight-gaining drugs. This change also helped reduce their overall diabetes medication load and improved blood sugar control.

Combining GLP-1 receptor agonists (specifically liraglutide) with bariatric surgery (BS) or endoscopic bariatric therapy (EBT) significantly enhances weight loss and metabolic improvements compared to BS or EBT alone, particularly in patients experiencing weight regain or insufficient loss.

If you have had bariatric surgery or an endoscopic procedure but are regaining weight or hitting a plateau, adding a GLP-1 receptor agonist like liraglutide (titrated to 3mg daily) can significantly boost weight loss and metabolic health compared to the procedure alone. This is particularly effective for those who have regained weight after surgery. Expect potential gastrointestinal side effects like nausea, which often subside with dose titration. This approach is not a replacement for lifestyle changes but a powerful adjunct to them.

Higher dietary protein intake (25-30% of daily kcal) improves cardiometabolic health markers, including insulin sensitivity and blood pressure, particularly when combined with energy restriction or specific protein sources like milk protein isolate.

If you are insulin resistant or overweight, increasing protein to 25-30% of your calories (especially from sources like milk protein or lean meats) alongside a calorie deficit can significantly improve your blood sugar control and insulin sensitivity. Focus on the quality of the protein source and the overall food matrix.

Ingesting a substantial mixed meal immediately after resistance exercise suppresses muscle protein breakdown (MPB) more effectively than consuming the same meal before exercise or exercising in a fasted state.

If you resistance train in the morning, prioritize eating a substantial meal containing protein and carbohydrates immediately after your workout. This timing is more effective at stopping muscle breakdown than eating the same meal before you train or skipping the meal entirely. Ensure your post-workout meal is nutrient-dense (e.g., whole foods) to maximize the insulin response that suppresses breakdown.

Combining dulaglutide (1.5 mg weekly) with a low-energy diet (825 kcal/day) significantly improves weight loss and glycaemic control in individuals with type 2 diabetes and obesity compared to baseline, while maintaining high adherence and tolerability.

If you have type 2 diabetes and obesity, combining a once-weekly GLP-1 medication (dulaglutide) with a strict low-calorie diet (around 825 calories/day) can lead to significant weight loss (approx. 9.5 kg) and better blood sugar control. This approach helps manage hunger, making it easier to stick to the diet. Always consult your doctor before stopping current diabetes or blood pressure medications.

Anti-obesity medications (AOMs), particularly semaglutide, produce statistically significant weight reduction in older adults (≥65 years), with the strongest evidence supporting their use in those with established cardiovascular disease.

If you are 65 or older and have obesity, anti-obesity medications like semaglutide can help you lose weight, especially if you have heart disease. The weight loss is significant (around 7-8% in major trials), but you may experience more side effects like nausea or dizziness. Work with your doctor to start slowly and monitor your health.

A 12-week low-carbohydrate, high-fat (LCHF) diet improves metabolic health outcomes (specifically triglycerides, HDL cholesterol, and glucose) and yields greater weight loss compared to a conventional high-carbohydrate, low-fat diet in overweight military personnel.

Adopt a low-carbohydrate, high-fat diet for 12 weeks, focusing on whole foods like non-starchy vegetables, meat, and healthy fats, while limiting processed foods, grains, and sugars. Monitor your adherence and expect improvements in metabolic markers like triglycerides and HDL, along with weight loss, even if LDL cholesterol increases slightly.

Supplementing with 20g/day of medium-chain triglycerides (MCTs) starting 5 days before a very low-calorie ketogenic diet (VLCKD) significantly enhances weight loss, fat mass reduction, and BMI class improvement compared to VLCKD alone.

If you are starting a strict ketogenic diet, consider taking 20g of MCT oil daily starting 5 days before you begin the diet. This may help you enter ketosis faster and lose more weight and fat than starting the diet without it. Ensure you are following a very low-calorie plan.

Combining 16:8 TRE with exercise significantly reduces triglycerides and LDL cholesterol compared to exercise alone, with greater LDL-C reductions observed in men.

If you exercise regularly, adding a 16:8 time-restricted eating schedule may lead to small but significant improvements in triglycerides and LDL cholesterol (bad cholesterol) compared to exercising without dietary timing restrictions. Men may see greater improvements in LDL-C. These benefits are modest and should be viewed as part of a broader cardiometabolic risk-reduction plan.

Sustained nutritional ketosis achieved through a continuous remote care intervention (CCI) involving carbohydrate restriction (<30g/day initially) leads to significant improvements in glycemic control, weight loss, and diabetes remission in Type 2 Diabetes patients over 2 years, while reducing medication dependence without adverse effects on bone health.

To manage Type 2 Diabetes long-term, consider a continuous care approach that includes nutritional ketosis. Start with less than 30g of carbs per day, aiming for a blood ketone level of 0.5-3.0 mmol/L. Work with a healthcare team to monitor your progress and adjust medications as needed. This approach has been shown to improve blood sugar, reduce weight, and even reverse diabetes in many cases over 2 years, without harming bone health.

Regular physical exercise is the most effective non-pharmacological intervention for preventing and treating age-associated skeletal muscle changes (sarcopenia) by modulating anabolic/catabolic pathways and reducing oxidative stress.

To combat age-related muscle loss, engage in regular exercise combining aerobic activity (50-80% of your max heart rate, 2-3 times a week) and resistance training (50-80% of your one-rep max, 2 days a week). This approach is the most effective way to maintain muscle mass, strength, and functional capacity in older age.

A 12-week ketogenic Mediterranean diet (KEMEPHY) significantly improves metabolic and hormonal markers in overweight women with PCOS, including reductions in body weight, fat mass, insulin resistance, and androgens, alongside improvements in lipid profiles and sex hormone binding globulin.

For overweight women with PCOS, a 12-week ketogenic Mediterranean diet (approx. 1600-1700 kcal, <30g carbs) significantly reduces weight, fat mass, and insulin resistance while improving hormonal balance (lower testosterone, higher SHBG). This approach addresses the root hormonal drivers of PCOS more effectively than standard caloric restriction alone, though it requires strict adherence and medical supervision due to the small sample size of supporting evidence.

Beetroot juice supplementation improves cardiorespiratory endurance in athletes by increasing nitric oxide bioavailability, which enhances blood flow, mitochondrial efficiency, and exercise economy, particularly in normoxic conditions.

If you are a trained endurance athlete, consuming beetroot juice providing 5-8 mmol of nitrate 2-3 hours before exercise may improve your efficiency and time to exhaustion, particularly in normal oxygen conditions. However, do not expect guaranteed results, especially if you are training at high altitude or consuming caffeine simultaneously, as these factors may negate the benefits.

Younger individuals (≤50 years) experience more significant weight and waist circumference reductions from Survodutide compared to older individuals (>50 years).

If you are 50 years or younger, you may experience greater weight loss from Survodutide than those over 50. This is likely due to metabolic differences and fewer comorbidities in younger patients, but the drug remains effective across age groups.

Expanding access to GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for eligible populations in the US could avert approximately 43,719 deaths annually by reducing obesity-related mortality.

If you have a BMI of 30 or higher (or 27+ with conditions like diabetes), you are likely eligible for GLP-1 medications like semaglutide or tirzepatide. These drugs are highly effective for weight loss and can significantly reduce your risk of early death from obesity-related causes. The main barrier is not efficacy, but cost and insurance coverage. Discuss these options with your doctor and explore insurance coverage options or patient assistance programs, as expanded access policies may soon make these treatments more available and affordable.

Tirzepatide is the only obesity management medication shown to significantly reduce the Apnea-Hypopnea Index (AHI) and achieve remission of Obstructive Sleep Apnea Syndrome (OSAS) in patients with obesity.

If you have obesity and sleep apnea, Tirzepatide has been shown to significantly reduce the severity of your sleep apnea (AHI) and can lead to remission of the condition. This is a unique benefit not clearly demonstrated by other weight loss drugs in this review.

Weight loss efficacy from primary care interventions attenuates over time, with an average regain of 0.53 kg per 6 months, even when the intervention continues.

Don't expect your weight loss to stay perfectly static. Even with ongoing treatment, you may regain about 0.5 kg every 6 months. This is normal. To maintain your loss, you likely need to stay on your treatment plan (including medication if used) long-term, rather than treating it as a short-term fix.

Anti-obesity medication (AOM) administered in primary care settings produces approximately double the weight loss (-2.94 kg) compared to non-pharmacologic interventions, but efficacy attenuates over time at a rate of 0.44 kg per six months.

If you are seeking weight loss in primary care, expect that adding medication to lifestyle changes will roughly double your weight loss compared to lifestyle changes alone. However, be prepared for this to be a long-term commitment; stopping the medication often leads to regaining the weight because your body fights to maintain the lower weight. Consistency and long-term use are key to maintaining results.

Low-Carbohydrate diets are more effective in reducing HbA1c in the short term (<12 months), in smaller studies, and in patients aged 60 years or older.

If you are over 60 years old with Type 2 Diabetes, a Low-Carbohydrate diet may offer superior HbA1c reduction compared to other diets, especially if you can maintain it for less than a year. This subgroup benefit was not as pronounced in younger or longer-term studies.

Omega-3 fatty acid supplementation attenuates muscle loss and accelerates recovery during periods of muscle disuse (immobilization) in young women.

If you are a young woman facing temporary immobilization (e.g., injury/surgery), taking ~3g EPA and ~2g DHA daily before and during the immobilization period may help preserve muscle volume and speed up recovery compared to not taking omega-3s.

Obesity exacerbates age-related anabolic resistance, leading to impaired muscle protein synthesis (MPS) response to nutrition and exercise, resulting in poor muscle quality despite preserved mass.

If you are older and obese, your muscles may not respond to protein and exercise as well as a younger or leaner person's. This is called 'anabolic resistance.' It means you might need to pay extra attention to protein intake and resistance training to maintain muscle quality, even if your muscle mass looks okay. Don't give up if progress feels slow; it's a biological hurdle, not a personal one.

Adjunct treatment with once-weekly semaglutide (max 0.5 mg) induces significant weight loss in non-diabetic patients experiencing weight regain or insufficient weight loss after bariatric surgery.

If you have had bariatric surgery and are regaining weight or haven't lost enough, talk to your doctor about adding once-weekly semaglutide. This study shows it can help you lose significant weight (over 10% in 6 months) even at a lower dose (0.5 mg) than what is typically used for non-surgical obesity. It is a safe adjunct to lifestyle changes and may help you avoid more invasive revision surgery.